NCT04276233View on ClinicalTrials.gov

Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

October 28, 2023

Study Completion Date

October 28, 2023

Conditions
Asthma
Interventions
DRUG

Mepolizumab

Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.

DRUG

Salbutamol

Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.

Trial Locations (14)

110096

GSK Investigational Site, New Delhi

201301

GSK Investigational Site, Noida

208005

GSK Investigational Site, Kanpur

302039

GSK Investigational Site, Jaipur

380013

GSK Investigational Site, Ahmedabad

380052

GSK Investigational Site, Ahmedabad

400008

GSK Investigational Site, Byculla Mumbai

411001

GSK Investigational Site, Pune

411004

GSK Investigational Site, Pune

440012

GSK Investigational Site, Nagpur

500018

GSK Investigational Site, Hyderabad

500038

GSK Investigational Site, Hyderabad

500082

GSK Investigational Site, Hyderabad

700014

GSK Investigational Site, Kolkata

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Tech Observer

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT04276233 - Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma | Biotech Hunter | Biotech Hunter